Anastrozole: In early breast cancer

Drugs

Volumn 62, Issue 17, 2002, Pages 2483-2490

  Wellington, Keri ^a   Faulds, Diana M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; HORMONE RECEPTOR; TAMOXIFEN;

BRAIN ISCHEMIA; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EARLY CANCER; ENDOMETRIUM CANCER; HOT FLUSH; HUMAN; MUSCULOSKELETAL DISEASE; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; VAGINA BLEEDING; VAGINA DISCHARGE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NITRILES; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 0036453626     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Buzdar A, Howell A. Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001 Sep; 7: 2620-35
2. Tsangaris T, Robert N, Love N. Update on treatment of early breast cancer: The trend toward less surgery, more systemic therapy. Postgrad Med 1999 May 15; 105: 81-102
3. Buzdar A. The place of chemotherapy in the treatment of early breast cancer. Br J Cancer 1998 Sep; 78 Suppl. 4: 16-20
4. AstraZeneca Pharmaceuticals LP. Arimidex® (Anastrozole) Tablets: Prescribing Information [Online]. Available from URL: http://www.fda.gov/cder/approval/index.htm [Accessed 2002 Sep 7]
5. Wiseman LR, Adkins JC. Anastrozole: A review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 1998 Oct; 13 (4): 321-32
6. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996 Oct; 74 (8): 1286-91
7. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002 Feb 1; 20: 751-7
8. Geisler J, Detre S, Berntsen H, et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001 May; 7: 1230-6
9. Miller WR, Stuart M, Dixon JM. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. Br J Cancer 2002 Oct 21; 87 (9): 950-5
10. Dowsett M, Donaldson K, Tsuboi M, et al. Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women. Cancer Chemother Pharmacol 2000 Jul; 46: 35-9
11. Plourde PV, Dyroff M, Dukes M. Arimidex®: A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994; 30 (1): 103-11
12. Yates RA, Dowsett M, Fisher GV, et al. Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996; 73 (4): 543-8
13. Martinetti A, Bajetta E, Buzzoni R, et al. Biological study of anastrozole in post-menopausal advanced breast cancer patients: Effects on bone metabolism and oestrogen suppression [abstract no. 719]. Eur J Cancer 2001 Oct; 37 Suppl. 6: 197
14. Esparza-Guerra L, Buzdar A. Anastrozole 'Arimidex' does not impair adrenal cortisol or aldosterone synthesis in postmenopausal women with advanced breast cancer [abstract no. 1954]. 37th Annual Meeting of the American Society of Clinical Oncology 2001 May 12; 20 (Pt 2): 52b
15. Mosby Inc., Anastrozole. Mosby's GenRx: A Comprehensive Reference for Generic and Brand Prescription Drugs. 11 Ed. St. Louis (MO): Mosby Inc., 2001: III-164-6
16. The ATAC Trialists' Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the 'Arimidex™ and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer 2001 Aug 3; 85 (3): 317-24
17. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. 43 Ed. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2002
18. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002 Jun 22; 359 (9324): 2131-9
19. Fallowfield L. on behalf of the ATAC Trialists' Group. Assessing the quality of life (QOL) of postmenopausal (PM) women randomized into the ATAC ('Arimidex', tamoxifen, alone or in combination) adjuvant breast cancer (BC) trial [abstract no. 159]. 38th Annual Meeting of the American Society of Clinical Oncology; 2002 18 May; Orlando, FL21 (Pt 1): 40a
20. Duffy SRG, Jackson TL. on behalf of the ATAC Trialists' Group. The ATAC ('Arimidex', tamoxifen, alone or in combination) early breast cancer (EBC) trial in postmenopausal (PM) patients: Endometrial sub-protocol results [abstract no. 158]. 38th Annual Meeting of the American Society of Clinical Oncology; 2002 18 May; Orlando, FL21 (Pt 1): 40a